Prostatype Genomics Ab Stock Current Valuation
Valuation analysis of Prostatype Genomics helps investors to measure Prostatype Genomics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Prostatype Genomics AB Company Current Valuation Analysis
Prostatype Genomics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Prostatype Genomics Current Valuation | 20.62 M |
Most of Prostatype Genomics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Prostatype Genomics AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Prostatype Genomics AB has a Current Valuation of 20.62 M. This is 99.86% lower than that of the Healthcare sector and 99.74% lower than that of the Diagnostics & Research industry. The current valuation for all Sweden stocks is 99.88% higher than that of the company.
Prostatype Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Prostatype Genomics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Prostatype Genomics could also be used in its relative valuation, which is a method of valuing Prostatype Genomics by comparing valuation metrics of similar companies.Prostatype Genomics is currently under evaluation in current valuation category among its peers.
Prostatype Fundamentals
| Return On Equity | -0.7 | |||
| Return On Asset | -0.39 | |||
| Operating Margin | (23.61) % | |||
| Current Valuation | 20.62 M | |||
| Shares Outstanding | 22.86 M | |||
| Shares Owned By Insiders | 1.00 % | |||
| Shares Owned By Institutions | 13.47 % | |||
| Price To Book | 1.14 X | |||
| Price To Sales | 34.59 X | |||
| Revenue | 10 K | |||
| Gross Profit | (5.98 M) | |||
| EBITDA | (15.46 M) | |||
| Net Income | (15.63 M) | |||
| Cash And Equivalents | 7.66 M | |||
| Cash Per Share | 0.58 X | |||
| Total Debt | 866.67 K | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 3.10 X | |||
| Book Value Per Share | 1.50 X | |||
| Cash Flow From Operations | (16.08 M) | |||
| Earnings Per Share | (1.22) X | |||
| Target Price | 21.02 | |||
| Beta | 1.22 | |||
| Market Capitalization | 42.29 M | |||
| Total Asset | 40.2 M | |||
| Z Score | 28.8 | |||
| Net Asset | 40.2 M |
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Prostatype Stock
Prostatype Genomics financial ratios help investors to determine whether Prostatype Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prostatype with respect to the benefits of owning Prostatype Genomics security.